SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

by Michal Mielcarek, Caroline L Benn, Sophie A Franklin, Donna L Smith, Ben Woodman, Paul A Marks, Gillian P Bates
Published 2011-01-01

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.

by Michal Mielcarek, Christian Landles, Andreas Weiss, Amyaouch Bradaia, Tamara Seredenina, Linda Inuabasi, Georgina F Osborne, Kristian Wadel, Chrystelle Touller, Rachel Butler, Janette Robertson, Sophie A Franklin, Donna L Smith, Larry Park, Paul A Marks, Erich E Wanker, Eric N Olson, Ruth Luthi-Carter, Herman van der Putten, Vahri Beaumont, Gillian P Bates
Published 2013-11-01